期刊文献+

基因多态性与晚期胃癌化疗关系的研究进展 被引量:4

下载PDF
导出
摘要 胃癌是全球常见的恶性肿瘤,化疗是晚期胃癌主要的治疗手段之一。与最佳支持治疗相比,化疗可提高晚期胃癌患者的生活质量,延长患者生存期。晚期胃癌尚无全球范围的标准化疗方案。近年来围绕5-FU前药、紫杉类及铂类等第三代新药进行了大量相关临床研究,不同的化疗方案产生不同的疗效,然而不同患者对同样的化疗方案敏感性也存在显著差异,这可能和个体遗传基因的多态性有关。基因多态性是指至少两种基因型存在于某一人群中的单基因性状。其主要表现在单个核苷酸多态性(SNP)。基因多态性决定了种族、个体之间的差异,(基因多态性)其与药物(包括抗肿瘤药物)治疗的反应性的关系亦日益受到人们的重视。
作者 陈俊 熊建萍
出处 《江西医药》 CAS 2010年第7期718-720,共3页 Jiangxi Medical Journal
  • 相关文献

参考文献17

  • 1N.Boku,S Yamamoto,K Shirao,et al.Randomized phase Ⅲ study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin(CP)versus S-1 alone in advanced gastric cancer (JCOG9912).J C Oncol,2007,25(18S):LBA4513.
  • 2Toriumi F,Kubota T,Saikawa Y,et al.Thymidylate synthetase (TS)genotype and TS/dihydropyrimidine dehydrogenase mRNA level as an indicator in determining chemosensitivity to 5-fluorouracil in advanced gastric carcinoma.Anticancer Res,2004,24(4):2455.
  • 3轩菡,顾康生,冯继峰,吴建中.胸苷酸合成酶基因多态性与氟尿嘧啶治疗晚期胃癌疗效相关性的研究[J].临床肿瘤学杂志,2008,13(7):594-597. 被引量:6
  • 4Mandola MV,Stoehlmacher J,Zhang W,et al.A 6bp polymerphism in the thymidylate synthaes gene causes message instability and is associated with decreased intratumoral TSmRNA levels.Pharmacogenetics,2004,14(5):319.
  • 5Merkelbach-Bruse S,Hans V,Mathiak M,et al.Associations between polymorphisms in the thymidylate synthase gene,the expression of thymidylate synthase mRNA and the microsatellite instability phenotype of colorectal cancer.Oncol Rep,2004,1l(4):839.
  • 6YK.Kang,WK.Kang,DB.Shin,et al.Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer:a randomised phase Ⅲ noninferiority trial.Annf Oncol,2009,20(4):666.
  • 7Spindler KL,Andersen RF,Jensen LH,et al.EGF61A>G polymorphism as predictive marker of clinical outcome to first-line capecitabine and oxaliplatin in metastatic colorectal cancer.Annals of Oncology,2009,10(22):1.
  • 8Xiao H,Verdier P,Fernandez N,et al.Insights into the mechanism of microtubule stabilization by taxol.Proc Nail Acad Sci,2006,103(27):10166.
  • 9Hari M,Loganzo F,Annable T,et al.Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu)and less stable microtubules.Mol Cancel Ther,2006,5(2):270.
  • 10Cunningham D,Starling N,Rao,S Iveson,T,et al.Capecitabine and oxaliplatin for advanced esophagogastric cancer.N Engl J Med,2008,358(1):36.

二级参考文献20

共引文献13

同被引文献41

  • 1闫婧,钱晓萍,刘宝瑞.精确放射治疗技术在老年肿瘤患者治疗中的应用[J].实用老年医学,2013,27(1):11-14. 被引量:6
  • 2王林波,陈文军,潘滔,宋向阳,陈大方,何超,吴金民.天地欣影响消化道恶性肿瘤微转移的初步研究[J].中华肿瘤杂志,2004,26(8):504-505. 被引量:15
  • 3许杜娟,陈敏珠.黄芪多糖的抑瘤作用及其机制[J].中国医院药学杂志,2005,25(10):923-925. 被引量:96
  • 4孙燕,石元凯.临床肿瘤内科手册[M].第5版.北京:人民卫生出版社,2009:606-607.
  • 5Rivera F,C Vega Villegas ME,Lopez Brea MF. Chemotherapy ofadvanced gastric cancer[J]. Cancer Treat Rev, 2007,33(4) : 315.
  • 6Sasaki T,Maeda Y, Kobayashi T,et al. Standard chemotherapy for gastrointestinal malignancies based on evidence[J]. GanTo Kagaku Ryoho ,2000,27 (2) : 166-176.
  • 7Giuliani F,Gebbia V,De Vita F,et al. Docetaxel as salvage thera py in advanced gastric cancer a phase study of the Gruppo On- cologico Italia Meridionale[J]. Anticancer Res,2003,23(5):4219- 4222.
  • 8Trumper M, Ross PJ, Cunninghan D ,et al.Efficacy andtolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer:A pooled analysis of three clinical trims [J].Eur J Cancer, 2006,42 : 827.
  • 9Saif MW, Katirtzoglou NA, Syrigos KN. Capecitabine:an overview of the side effects and their management [J].Anticancer Drugs ,2008, 19(5): 447 -464.
  • 10Van Cutsem E, Moiseyenko VM,Tjulandin S, et al. Phase III studyof docetaxel and cisp latin plus fluorouracil compared with cisp lati- hand fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group[J]. JClin Oncol,2006,24:4991.

引证文献4

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部